Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

Chundsell MedicalsChundsell Medicals

Chundsell Medicals

Why invest in Chundsell Medicals

  • By providing new and personalized information, Chundsell is actively involved in the radical transformation of prostate cancer healthcare with its Prostatype® Test System (PrTS)
  • Significant market opportunity in prostate cancer market segment: 630 MEUR annually
  • Studies indicate over‐ and undertreatment of 7 out of 10 prostate cancer patients
  • Ready for market: CE‐approved, IP protected and ISO 13485:2012 certified
  • Clinical studies with early adopters validates PrTS – concluded and ongoing studies
  • First commercial installation of PrTS expected second half of 2016
  • Highly scalable business model with recurring sales
  • Chundsell is improving patients’ quality of life while reducing healthcare costs:
  •      combining genetic testing using stem cell gene signatures,
  •      with advanced data analysis (unique proprietary patient database and algorithm),
  •      evolution towards personalized medicine in prostate cancer healthcare,
  • Chundsell Medicals has and will conduct all its activities based on good ethics for the patients.

Chundsell Medicals seeks 20.0 MSEK at a pre‐money valuation of 89.7 MSEK, entailing 18.2% ownership and 16.5% ownership fully diluted. The proceeds are intended to support and accelerate our commercialisation process.

Why invest in Chundsell Medicals

  • By providing new and personalized information, Chundsell is actively involved in the radical transformation of prostate cancer healthcare with its Prostatype® Test System (PrTS)
  • Significant market opportunity in prostate cancer market segment: 630 MEUR annually
  • Studies indicate over‐ and undertreatment of 7 out of 10 prostate cancer patients
  • Ready for market: CE‐approved, IP protected and ISO 13485:2012 certified
  • Clinical studies with early adopters validates PrTS – concluded and ongoing studies
  • First commercial installation of PrTS expected second half of 2016
  • Highly scalable business model with recurring sales
  • Chundsell is improving patients’ quality of life while reducing healthcare costs:
  •      combining genetic testing using stem cell gene signatures,
  •      with advanced data analysis (unique proprietary patient database and algorithm),
  •      evolution towards personalized medicine in prostate cancer healthcare,
  • Chundsell Medicals has and will conduct all its activities based on good ethics for the patients.

Chundsell Medicals seeks 20.0 MSEK at a pre‐money valuation of 89.7 MSEK, entailing 18.2% ownership and 16.5% ownership fully diluted. The proceeds are intended to support and accelerate our commercialisation process.

Annual & quarterly reports
Image showing Chundsell Medicals' Logo

Chundsell Medicals

Why invest in Chundsell Medicals

  • By providing new and personalized information, Chundsell is actively involved in the radical transformation of prostate cancer healthcare with its Prostatype® Test System (PrTS)
  • Significant market opportunity in prostate cancer market segment: 630 MEUR annually
  • Studies indicate over‐ and undertreatment of 7 out of 10 prostate cancer patients
  • Ready for market: CE‐approved, IP protected and ISO 13485:2012 certified
  • Clinical studies with early adopters validates PrTS – concluded and ongoing studies
  • First commercial installation of PrTS expected second half of 2016
  • Highly scalable business model with recurring sales
  • Chundsell is improving patients’ quality of life while reducing healthcare costs:
  •      combining genetic testing using stem cell gene signatures,
  •      with advanced data analysis (unique proprietary patient database and algorithm),
  •      evolution towards personalized medicine in prostate cancer healthcare,
  • Chundsell Medicals has and will conduct all its activities based on good ethics for the patients.

Chundsell Medicals seeks 20.0 MSEK at a pre‐money valuation of 89.7 MSEK, entailing 18.2% ownership and 16.5% ownership fully diluted. The proceeds are intended to support and accelerate our commercialisation process.

Why invest in Chundsell Medicals

  • By providing new and personalized information, Chundsell is actively involved in the radical transformation of prostate cancer healthcare with its Prostatype® Test System (PrTS)
  • Significant market opportunity in prostate cancer market segment: 630 MEUR annually
  • Studies indicate over‐ and undertreatment of 7 out of 10 prostate cancer patients
  • Ready for market: CE‐approved, IP protected and ISO 13485:2012 certified
  • Clinical studies with early adopters validates PrTS – concluded and ongoing studies
  • First commercial installation of PrTS expected second half of 2016
  • Highly scalable business model with recurring sales
  • Chundsell is improving patients’ quality of life while reducing healthcare costs:
  •      combining genetic testing using stem cell gene signatures,
  •      with advanced data analysis (unique proprietary patient database and algorithm),
  •      evolution towards personalized medicine in prostate cancer healthcare,
  • Chundsell Medicals has and will conduct all its activities based on good ethics for the patients.

Chundsell Medicals seeks 20.0 MSEK at a pre‐money valuation of 89.7 MSEK, entailing 18.2% ownership and 16.5% ownership fully diluted. The proceeds are intended to support and accelerate our commercialisation process.

Annual & quarterly reports